by Staff Writers
Nairobi (AFP) June 28, 2017
The generic version of the most advanced drug against HIV has been introduced in Kenya, a first in Africa where more than 25 million have the disease, the NGO Unitaid said Wednesday.
The drug, Dolutegravir (DTG) is the anti-retroviral drug of choice for those living with HIV in developed countries, but its high price has put it out of reach for most struggling with the disease in Africa.
"The generic DTG has two advantages: on the one hand, it is very good from a pharmaceutical point of view. On the other hand, it is much cheaper," said Robert Matiru of Unitaid, which works to reduce the costs of medicines treating AIDS, tuberculosis or malaria.
He described the drug as "the most effective HIV treatment currently on the market."
A box of 30 pills of DTG, which lasts a month, costs between $25 (21 euros) and $50. The generic version only costs $4.
Kenya has already started rolling out the new drug, which will initially be provided for free to 27,000 people living with HIV who are intolerant to the side effects of the current best drug used in the country.
It will become available nationwide later in the year, and will also be rolled out in Nigeria and Uganda.
The drug is easier to take than those currently on the market, requiring only one pill a day, causing fewer side effects, and patients are less likely to develop resistance, said Matiru.
Around 37 million people live with HIV/AIDS around the world, 70 percent of them in Africa, according to 2015 statistics from the World Health Organisation (WHO).
Colombo (AFP) June 26, 2017
Sri Lanka has suffered a record 200 deaths from dengue fever this year, the health minister said Monday, blaming a garbage disposal crisis in Colombo. Rotting garbage has been piling up in many parts of the capital since the country's main rubbish tip collapsed in April, crushing dozens of homes and killing 32 people. With nowhere to take the trash, municipal collection has drastically s ... read more
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2017 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement|